Greater cumulative exposure to antibiotics during hospitalization was associated with the subsequent emergence of multidrug-resistant organisms in patients with advanced chronic liver disease, with resistance risk increasing at different exposure levels depending on the antibiotic class, according to a prospective cohort study published in Clinical Infectious Diseases.
Newly detected multidrug-resistant organisms during follow-up were also independently associated with increased 180-day mortality, whereas overall resistance detected at baseline was not.
Lead author Myriam W. Heilani, MD, of Goethe University Frankfurt’s University Hospital in Germany, and colleagues said the findings support considering cumulative antibiotic exposure, rather than treatment duration alone, when making antimicrobial stewardship decisions in patients with advanced cirrhosis.
Tracking antibiotic exposure and resistance
The prospective study included 256 adults with advanced chronic liver disease enrolled at University Hospital Frankfurt from November 2020 through June 2023. Most patients had decompensated cirrhosis, and the median age was 59 years.
Patients underwent oral and rectal screening for multidrug-resistant organisms at study admission and subsequent hospital readmissions. Investigators also recorded antibiotics administered during hospitalization and quantified cumulative exposure using defined daily doses, a standardized measure of antibiotic use.
The primary analysis focused on 246 patients who had no multidrug-resistant organisms detected on their first hospital admission screening swab. Of these, 235 (95.5%) underwent at least one follow-up screening, while 11 were lost to follow-up before another sample could be obtained.
Investigators tracked antibiotic exposure during hospitalization and screened patients during subsequent admissions to determine whether resistant organisms emerged over time.
During follow-up, 49 patients, or 19.9%, newly acquired vancomycin-resistant enterococci, and 28, or 11.4%, acquired a multidrug-resistant gram-negative organism.
Patients who developed vancomycin-resistant enterococci had significantly greater cumulative exposure to antibiotics overall, as well as to beta-lactam/beta-lactamase inhibitor combinations and glycopeptides. For multidrug-resistant gram-negative organisms, cumulative antibiotic exposure was generally higher among patients who acquired resistance, although only imipenem exposure reached statistical significance in direct group comparisons.
Risk rises with cumulative exposure
The investigators found that the risk of acquiring vancomycin-resistant enterococci increased as cumulative antibiotic exposure rose.
For any antibiotic, the estimated exposure associated with a 20% probability of acquiring vancomycin-resistant enterococci was 9.6 defined daily doses. That level was reached at lower cumulative exposures for several individual antibiotic classes: 5.1 defined daily doses for beta-lactam/beta-lactamase inhibitor combinations, 3.6 for piperacillin/tazobactam, 3.0 for cephalosporins, 3.3 for carbapenems and 1.5 for glycopeptides.
The pattern differed by antibiotic class. With beta-lactam/beta-lactamase inhibitor combinations and piperacillin/tazobactam, risk remained relatively low at first and then rose more sharply after greater exposure. With carbapenems and cephalosporins, risk increased more steadily as exposure accumulated.
The same general pattern was seen for multidrug-resistant gram-negative organisms, although the relationship was weaker. A 20% probability of acquisition was reached at 19.2 defined daily doses for any antibiotic, 8.9 for beta-lactam/beta-lactamase inhibitor combinations, 7.0 for carbapenems and 9.9 for piperacillin/tazobactam.
The authors said these estimated class-specific exposure thresholds could eventually help clinicians decide when to reassess or de-escalate antibiotic therapy. However, the thresholds were derived from observational data and require external validation before clinical use.
Newly acquired resistance associated with mortality
Across the full cohort, 93 of 256 patients, or 36.3%, had a multidrug-resistant organism detected at some point during their initial hospitalization. Of 139 multidrug-resistant isolates identified, 110 (79.1%) represented colonization rather than clinical infection.
Overall, multidrug-resistant organism detection at baseline was not associated with increased mortality, although organism-specific analyses identified significant associations for baseline resistant infections. Patients who newly acquired a resistant organism during follow-up had significantly higher 180-day mortality, even after accounting for other major risk factors.
In a competing-risk analysis accounting for liver transplantation and adjusting for acute-on-chronic liver failure and chronic kidney disease, newly detected multidrug-resistant organisms remained independently associated with 180-day mortality (hazard ratio = 2.15; 95% confidence interval, 1.27-3.64; P = .004).
The investigators cautioned that the observational design cannot fully separate the effects of antibiotic exposure, illness severity and hospital transmission. Sicker patients may both receive more antibiotics and undergo more microbiologic testing. Antibiotic exposure was also limited to treatment administered during hospitalization at the study center, potentially underestimating cumulative exposure.
The single-center study was conducted in a setting where vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Enterobacterales were prominent, potentially limiting the applicability of the findings to other hospitals.
The authors concluded that cumulative antibiotic exposure may be a modifiable risk factor for multidrug resistance in advanced cirrhosis and argued for stewardship decisions that account for total antibiotic burden, not just treatment duration.
Dr. Heilani reported speaking fees from AbbVie and travel support from Pfizer, both unrelated to the submitted work. Other authors reported consulting, advisory or speaking fees, travel support and research funding from multiple organizations.